资料显示，北大医药股份有限公司位于重庆市两江新区金开大道90号棕榈泉国际中心B座21楼，成立日 期1993年5月18日，上市日期1997年6月16日，公司主营业务涉及化学药品制剂的研发、生产和销售,医 药流通以及医疗服务等业务。主营业务收入构成为：药品34.69%，制剂药34.34%，医药器械及试剂 30.82%，其他(补充)0.13%，商品及材料销售0.03%。 1月13日，北大医药盘中上涨2.14%，截至09:55，报6.68元/股，成交8722.37万元，换手率2.21%，总市 值39.81亿元。 资金流向方面，主力资金净流入43.30万元，特大单买入493.12万元，占比5.65%，卖出435.43万元，占 比4.99%；大单买入1841.19万元，占比21.11%，卖出1855.58万元，占比21.27%。 北大医药今年以来股价涨9.33%，近5个交易日涨3.25%，近20日涨4.05%，近60日涨8.97%。 分红方面，北大医药A股上市后累计派现1.83亿元。近三年，累计派现8105.43万元。 机构持仓方面，截止2025年9月30日，北大医药十大流通股东中，广发量化多因子混合A（005225）位 ...

中经记者 陈婷 赵毅 深圳报道 公告显示，大新药业股东全部权益价值约为2.33亿元，增值率28.52%。西南合成持有大新药业9.75%的 股份，对应此次交易标的估值为2266.88万元。 北大医药收购大新药业股权构成关联交易。西南合成为北大医药控股股东，对其持股22.22%。2024年 及2025年前三季度，西南合成净资产均为负，截至2025年9月30日约为-15.95亿元。 十年前的一场资产腾挪，至今仍余波不断。 近日，北大医药（000788.SZ）完成一笔关联交易，以2200万元竞得控股股东西南合成医药集团有限公 司（以下简称"西南合成"）所持北大医药重庆大新药业股份有限公司（以下简称"大新药业"）9.75%股 权。 公告显示，上述交易标的处于质押登记状态，此前用于担保西南合成对外所负历史借款债务的清偿。 2024年，大新药业亏损超2700万元，2025年前8个月盈利6.36万元。北大医药方面称："公司有望在原料 药行业发展趋势向好的背景下，更为直接地分享产业链价值提升带来的潜在利润。" 事实上，大新药业曾是北大医药子公司，其92.26%股份在2015年11月被以近4.4亿元的价格出售给西南 合成，作为北 ...

融券方面，多瑞医药12月24日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，西藏多瑞医药股份有限公司位于武汉市江汉区中央商务区泛海国际SOHO城4号楼6层，成立 日期2016年12月22日，上市日期2021年9月29日，公司主营业务涉及化学药品制剂及其原料药的研发、 生产和销售业务。主营业务收入构成为：制剂37.60%，中间体35.78%，原料药21.64%，其他4.98%。 截至9月30日，多瑞医药股东户数6361.00，较上期减少16.60%；人均流通股12576股，较上期增加 19.90%。2025年1月-9月，多瑞医药实现营业收入1.37亿元，同比减少31.68%；归母净利润-7972.77万 元，同比减少366.82%。 12月24日，多瑞医药涨2.09%，成交额5929.02万元。两融数据显示，当日多瑞医药获融资买入额 1122.67万元，融资偿还633.65万元，融资净买入489.02万元。截至12月24日，多瑞医药融资融券余额合 计2.14亿元。 融资方面，多瑞医药当日融资 ...

12月23日，多瑞医药涨3.14%，成交额7260.89万元。两融数据显示，当日多瑞医药获融资买入额320.57 万元，融资偿还748.18万元，融资净买入-427.61万元。截至12月23日，多瑞医药融资融券余额合计2.09 亿元。 截至9月30日，多瑞医药股东户数6361.00，较上期减少16.60%；人均流通股12576股，较上期增加 19.90%。2025年1月-9月，多瑞医药实现营业收入1.37亿元，同比减少31.68%；归母净利润-7972.77万 元，同比减少366.82%。 分红方面，多瑞医药A股上市后累计派现5986.94万元。近三年，累计派现986.94万元。 责任编辑：小浪快报 融资方面，多瑞医药当日融资买入320.57万元。当前融资余额2.09亿元，占流通市值的5.08%，融资余 额超过近一年90%分位水平，处于高位。 融券方面，多瑞医药12月23日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元，超过近一年90%分位水平，处于高位。 资料显示，西藏多瑞医药股份有限公司位于武汉市江汉区中央商务区泛海国际SOHO城4号 ...

每经头条（nbdtoutiao）——海南封关政策红利全解析：零关税、低个税、投资准入放宽、跨境资金自 由、创业扶持…… （记者 曾健辉） 每经AI快讯，润都股份（SZ 002923，收盘价：12.42元）12月18日晚间发布公告称，截至本公告日，李 希累计质押股数约为6686万股，占公司总股本比例为19.96%。 2025年1至6月份，润都股份的营业收入构成为：化学药品制剂制造占比56.18%，原料药制造占比 42.61%，其他业务占比1.2%。 截至发稿，润都股份市值为42亿元。 免责声明：本文内容与数据仅供参考，不构成投资建议，使用前请核实。据此操作，风险自担。 每日经济新闻 ...

Core Viewpoint - The stock price of Koyuan Pharmaceutical has experienced a decline of 4.68% year-to-date, with significant drops over various trading periods, indicating potential challenges in the company's market performance [2]. Company Overview - Koyuan Pharmaceutical, established on December 27, 2004, is located in Shandong, Jinan, and was listed on April 4, 2023. The company specializes in the research, production, and sales of chemical raw materials, finished pharmaceuticals, and pharmaceutical intermediates [2]. - The revenue composition of Koyuan Pharmaceutical is as follows: 44.77% from chemical raw materials, 41.41% from chemical drug formulations, 12.47% from intermediates, and 1.35% from other sources [2]. Stock Performance - As of December 3, Koyuan Pharmaceutical's stock price was 28.32 CNY per share, with a market capitalization of 3.067 billion CNY. The stock has seen a trading volume of 25.76 million CNY and a turnover rate of 1.31% [1]. - The stock has declined by 4.61% over the last five trading days, 10.38% over the last 20 days, and 19.09% over the last 60 days [2]. Financial Performance - For the period from January to September 2025, Koyuan Pharmaceutical reported a revenue of 303 million CNY, a year-on-year decrease of 8.52%. The net profit attributable to shareholders was 31.47 million CNY, down 20.69% year-on-year [2]. - The company has distributed a total of 85.085 million CNY in dividends since its A-share listing [3]. Shareholder Information - As of September 30, 2025, Koyuan Pharmaceutical had 11,100 shareholders, a decrease of 11.26% from the previous period. The average number of circulating shares per shareholder increased by 12.69% to 6,211 shares [2]. - Notably, CITIC Prudential Multi-Strategy Mixed Fund (LOF) A has exited the list of the top ten circulating shareholders [3].

校 对： 吕久彪 百万用户都在看 刚刚！"18罗汉"，突然异动！ 直线拉升！三大利好，集中来袭！ 美国，传出大消息！ 特朗普，最新发声！ 涨停潮！A股盘中，集体拉升！ 违法和不良信息举报电话：0755-83514034 邮箱：bwb@stcn.com 11月12日，北大医药股份有限公司（简称北大医药）公告，公司于近日经有关部门核实，获悉公司董事 长、总裁徐晰人因涉嫌刑事犯罪，已被重庆市江北区人民检察院批准逮捕。 此前，北大医药曾公告，公司董事长、总裁徐晰人被刑事拘留，正在配合相关部门调查，暂时无法正常履 职。 北大医药主要从事化学药品制剂的研发、生产和销售，医药流通以及医疗服务等业务。其制剂产品主要覆 盖抗感染类、镇痛类、精神类、消化系统类、心血管类等。其流通业务通过北医医药、武汉叶开泰两家全 资子公司，从事第三方药品、器械和耗材的分销、零售、医院集采、药房托管等业务。 西南合成医药集团为北大医药第一大股东，直接持股22.22%。徐晰人通过西南合成医药集团间接持有北 大医药132,455,475股股份，占总股本比例为22.22%，为北大医药实际控制人。 简历显示，徐晰人于1979年4月出生。2025年4月，北 ...

Core Viewpoint - Nanjing Pharmaceutical's stock price has shown significant volatility, with a year-to-date increase of 51.38% but a recent decline in the last 60 days by 27.90% [2][3] Company Overview - Nanjing Pharmaceutical, established on December 27, 2006, and listed on March 26, 2020, focuses on the research, production, and sales of antiviral and infectious disease treatment drugs, as well as medications for major diseases like cardiovascular diseases and diabetes [2] - The company operates entirely in the chemical drug formulation sector, with 100% of its revenue derived from this area [2] Financial Performance - For the period from January to September 2025, Nanjing Pharmaceutical reported a revenue of 83.15 million yuan, a year-on-year decrease of 66.89%, and a net profit attributable to shareholders of -68.63 million yuan, reflecting a 19.96% decline [3] - The company has not distributed any dividends in the last three years, with a total payout of 40.74 million yuan since its A-share listing [4] Shareholder Information - As of September 30, 2025, the number of shareholders increased by 49.13% to 14,100, while the average number of tradable shares per person decreased by 32.95% to 19,441 shares [3] - New institutional shareholders include several funds from GF Fund Management, indicating a shift in the shareholder base [4] Market Activity - Nanjing Pharmaceutical's stock experienced a net outflow of 529,500 yuan in major funds, with significant buying and selling activity observed [1] - The stock has appeared on the "Dragon and Tiger List" seven times this year, indicating notable trading activity [2]

Group 1 - The core viewpoint of the news is that Duorui Pharmaceutical has shown significant fluctuations in its financial performance and trading activities, with a notable decrease in revenue and net profit in the recent reporting period [1][2]. Group 2 - On November 11, Duorui Pharmaceutical's stock price increased by 0.02%, with a trading volume of 89.78 million yuan. The financing buy-in amount for the day was 12.24 million yuan, while the financing repayment was 11.49 million yuan, resulting in a net financing buy-in of 0.75 million yuan [1]. - As of November 11, the total financing and securities lending balance for Duorui Pharmaceutical was 190 million yuan, which accounts for 4.20% of its circulating market value, indicating a high level of financing compared to the past year [1]. - The company has not engaged in any securities lending activities on November 11, with both the securities lending repayment and selling amount recorded as zero [1]. - Duorui Pharmaceutical, established on December 22, 2016, and listed on September 29, 2021, focuses on the research, production, and sales of chemical drug formulations and their raw materials. The revenue composition is as follows: formulations 37.60%, intermediates 35.78%, raw materials 21.64%, and others 4.98% [1]. Group 3 - As of September 30, the number of shareholders for Duorui Pharmaceutical was 6,361, a decrease of 16.60% from the previous period. The average circulating shares per person increased by 19.90% to 12,576 shares [2]. - For the period from January to September 2025, Duorui Pharmaceutical reported a revenue of 137 million yuan, a year-on-year decrease of 31.68%. The net profit attributable to the parent company was -79.73 million yuan, reflecting a significant year-on-year decline of 366.82% [2]. - Since its A-share listing, Duorui Pharmaceutical has distributed a total of 59.87 million yuan in dividends, with 9.87 million yuan distributed over the past three years [2].

Company Overview - Founded on May 18, 1993, and listed on the Shenzhen Stock Exchange on June 16, 1997, the company is a university-affiliated pharmaceutical enterprise with a comprehensive pharmaceutical platform covering research, production, and sales [1] - The company primarily engages in the research, production, and sales of chemical drug formulations, as well as pharmaceutical distribution and medical services, and is classified under the pharmaceutical and biological - chemical pharmaceuticals - chemical formulations sector [1] Financial Performance - For Q3 2025, the company's revenue was 1.231 billion yuan, ranking 44th among 110 companies in the industry, while the industry leader, Huadong Medicine, reported revenue of 32.664 billion yuan [2] - The net profit for the same period was 136 million yuan, placing the company 45th in the industry, with the top performer, Heng Rui Medicine, achieving a net profit of 5.76 billion yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 23.09%, down from 34.01% in the previous year, which is below the industry average of 35.26%, indicating lower debt pressure [3] - The gross profit margin for the same period was 27.03%, slightly down from 27.75% year-on-year, and significantly lower than the industry average of 57.17%, suggesting a need for improvement in profitability [3] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 2.88% to 49,400, with an average holding of 12,100 circulating A-shares, which increased by 2.97% [5] - Among the top ten circulating shareholders, Guangfa Quantitative Multi-Factor Mixed A (005225) is the sixth largest, holding 2.278 million shares as a new shareholder [5] Leadership - The controlling shareholder is Southwest Synthetic Pharmaceutical Group Co., Ltd., with Xu Xiren as the actual controller, who is also the chairman of the company and has a background in banking [4]